Alectinib, an ALK inhibitor, Has a DFS Advantage in Early NSCLC.

Published Date: 24 Oct 2023

The ALINA trial's preliminary results indicate that in resected stage IB-IIIA NSCLC, adjuvant alectinib treatment improved overall survival compared with chemotherapy. Will the overall survival outcome match the early DFS results?

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Year in Review: Chronic Lymphocytic Leukemia

2.

According to a study, white Americans are overdiagnosing melanoma at an alarming rate.

3.

Approval in Endometrial Cancer Expanded; Masks at Cancer Centers; NPR Reporter Dies

4.

The First Gene Therapy Provides a Durable Response for Non-Muscle-Invasive Bladder Cancer.

5.

Canine Cancer Vaccine: A Potential Resurrection? U.S. KK. Snubs Enertu.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot